Skip To Main Content

Transplantační medicína

Nejnovější trendy

Prozkoumejte nejčtenější články a videa na Campus Sanofi

Seřadit

Have you observed any significant differences in treatment outcomes between these two therapies in your local practice?

Pompe Care Podcast Series 3

How has avalglucosidase alfa impacted the treatment paradigm for both infantile-onset and late-onset Pompe disease in your experience?

How can you see changing the lives of patient starting taking Nexviazyme and if you can share from your experience couple of patient stories that realy impacted positively from staring the treatment for Pompe disease?

From your experience

Pompe Care Podcast Series 2

What challenges do clinicians face in monitoring in disease progrission and response to therapy?

What has been your experience with switching patients from alglucosidase alfa to avalglucosidase alfa?

Current Treatment Landscape & hands on Experience

Pompe Care Podcast Series 3

Thank You!

The End

What makes avalglucosidase alfa different from alglucosidase alfa in terms of clinical efficacy and patient outcomes?

Advances in Therapy: Avalglucosidase Alfa & Future Innovations

4.4. Dr. Bakó Barnabás 1 - Mit kell tudnunk a szenzorokról?

1.5. Dr. Chmel Rita – Mi az a C-peptid?